Aspire Real Estate Investors, Inc. focuses on investing, developing, remodeling and managing a portfolio of multi-family properties in metropolitan areas of the United States. The company is headquartered in Irvine, California.
147 articles
ASP Isotopes Inc. disclosed a 15.1% beneficial ownership stake in ENDRA Life Sciences Inc., comprising common shares and pre-funded warrants. A proposed merger with Noble Africa LLC may grant ASP Isot
ASP Isotopes Inc. filed a Form 8K on October 2nd, indicating a significant corporate event. Specific details of the disclosure require reviewing the official filing.
ENDRA Life Sciences filed a Form S-4 registration statement to merge with Noble Africa, a subsidiary of ASP Isotopes. The deal aims to combine ASP's South African assets with a Nasdaq-listed entity pe
ENDRA filed a Form S-4 registration statement for its proposed merger with Noble Africa, a subsidiary of ASP Isotopes, incorporating material disclosures regarding Renergen and financial impacts.
ASP Isotopes director Robert John Andrew Ryan purchased 15,000 shares at an average price of $2.68, raising his direct holdings to 675,222 shares. The acquisition occurred across multiple transactions
ASP Isotopes Inc submitted a Form 4 regulatory filing on September 30, reflecting a 3.98% stock increase, according to an automated notification.
ASP Isotopes Inc. director Robert John Andrew Ryan purchased 8,000 shares at an average price of $2.70 per share. The transaction was reported via Form 4, signaling positive insider sentiment.
ASP Isotopes Inc. financial overview on the Hannover Stock Exchange shows a closed market with no trades, presenting an early-stage report structure without detailed revenue figures.
Halper Sadeh LLC is investigating ASP Isotopes Inc. officers for potential fiduciary breaches, offering free consultations to long-term shareholders seeking corporate governance reforms.
ASP Isotopes director Todd Wider filed notice to sell 200,000 shares worth $590,000 via J.P. Morgan, following two prior sales in June 2026.
At its inaugural Capital Markets Day, ASP Isotopes outlined a strategy targeting $300 million EBITDA by 2031 through nuclear medicine, helium, and LNG production, with commercial shipments commencing
ASP Isotopes targets $300 million EBITDA by 2031 following its inaugural Capital Markets Day, driven by liquid helium, radiopharmacy, and stable isotope commercialization. The company also announced p
ASP Isotopes Inc. COO Robert Ainscow sold 8,438 shares at $4.292 per share under a Rule 10b5-1 plan to cover tax withholding obligations on vested restricted stock awards.
ASP Isotopes Inc. is exploring a nuclear fuel conversion pilot in Namibia via subsidiary QLE to strengthen global fuel-cycle capabilities. The project leverages Namibia's uranium production to transit
ASP Isotopes Inc. submitted a filing under Securities Act Rule 425 concerning prospectuses and communications related to ongoing business combination transactions.
ASP Isotopes Inc. plans to commence commercial helium production and expand stable isotope facilities, including Silicon-28 and Carbon-14, within six months. Initial shipments from its South African p
ASP Isotopes outlined a plan to commercialize helium, isotopes, and nuclear fuel projects within six months to drive revenue. Key initiatives include silicon-28, carbon-14, and ytterbium-176 productio
ASP Isotopes' subsidiary Tetra4 has begun commissioning its Phase 1 liquid helium plant in South Africa, targeting first commercial shipments by September 2026. The project is projected to generate ov
ENDRA Life Sciences announced that ASP Isotopes' partner, Tetra4, has initiated commissioning for the liquid helium plant at the Virginia Gas Project. This marks a significant operational milestone fo
ASP Isotopes Inc.'s subsidiary Renergen has commenced commissioning a liquid helium plant in South Africa to address global shortages. Commercial shipments are anticipated by September 2026, with Phas
ASP Isotopes subsidiary Quantum Leap Energy is evaluating a pilot fluorination facility in Namibia for nuclear fuel cycle technologies. While entering public environmental review, no final investment
ASP Isotopes Inc. announced its subsidiary Quantum Leap Energy is evaluating metal conversion opportunities in Namibia. An environmental assessment is underway for a proposed pilot-scale hydrofluorina
ASP Isotopes Inc. submitted a Form 8K filing on August 18, leading to a 3.98% decline in its common stock price as reported by Investing.com.
ASP Isotopes reported Q2 2026 earnings with revenue reaching US$5.1 million, though stock valuation remains strained due to high multiples and dilution despite narrowing losses.
ASP Isotopes reported a quarterly loss of $0.28 per share, missing analyst estimates by $0.11. Shares fell 0.2% to $4.27 following the release, while insiders sold over $2 million worth of stock.
ASP Isotopes Inc. reported quarterly revenue of $5.1 million and narrowed its net loss to $34.0 million following the acquisition of Renergen. The deal diversified the company into helium and LNG sect
ASP Isotopes targets commercial isotope deliveries by late 2026, launching helium production in Virginia and expanding radiopharmacy capabilities via acquisitions and cyclotron technology integration.
ASP Isotopes secured a five-year take-or-pay LNG contract with a South African food processor for its Virginia Gas Project. The agreement covers 10% of Phase 1 capacity at over $16 per GJ, with produc
ASP Isotopes Inc. is set to release Q2 2026 earnings on August 14th, with analysts forecasting a $0.17 per share loss and $4.47 million revenue.
ASP Isotopes Inc. filed a Form 8K on August 6 according to Investing.com, though the announcement provided no further details regarding the specific contents of the filing.
ChemBrief